December 14, 2009 - 7:45 p.m.
Second Pivotal Phase III Study of Gilead's Darusentan for Resistant Hypertension Misses Primary Endpoints
Printer Friendly Version 
December 10, 2009 - 4:48 p.m.
FDA Advisory Committee Supports Use of Aztreonam for Inhalation Solution for Patients With Cystic Fibrosis
Printer Friendly Version 
November 24, 2009 - 4:32 p.m.
Gilead Sciences to Present at the NASDAQ OMX 23rd Investor Program
Printer Friendly Version 
November 24, 2009 - 9:04 a.m.
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Printer Friendly Version 
November 11, 2009 - 4:31 p.m.
Gilead Sciences to Present at the Lazard Capital Markets 6TH Annual Healthcare Conference on Tuesday, November 17
Printer Friendly Version 
November 04, 2009 - 4:32 p.m.
Gilead Sciences to Present at the 18th Annual Credit Suisse Healthcare Conference on Wednesday, November 11
Printer Friendly Version 
November 02, 2009 - 8:32 a.m.
Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension
Printer Friendly Version 
October 31, 2009 - 5:32 p.m.
Gilead Announces Long-Term Data from Two Pivotal Phase III Studies Evaluating Viread(R) For Chronic Hepatitis B
Printer Friendly Version 
October 30, 2009 - 4:32 p.m.
Gilead Sciences to Present at the Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3
Printer Friendly Version 
October 26, 2009 - 8:18 a.m.
Gilead's Aztreonam for Inhalation Solution to be Reviewed by FDA Anti-Infective Drugs Advisory Committee on December 10, 2009
Printer Friendly Version 
October 20, 2009 - 4:07 p.m.
Gilead Sciences Announces Record Third Quarter 2009 Financial Results
Printer Friendly Version 
October 13, 2009 - 4:32 p.m.
Gilead Sciences to Release Third Quarter 2009 Financial Results on Tuesday, October 20, 2009
Printer Friendly Version 
September 23, 2009 - 11:09 a.m.
European Commission Grants Conditional Marketing Authorization to Cayston(R) (Aztreonam Lysine) for the Treatment of Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis
Printer Friendly Version 
September 16, 2009 - 4:31 p.m.
Gilead Sciences to Present at the UBS Global Life Sciences Conference on Monday, September 21
Printer Friendly Version 
September 13, 2009 - 6:45 p.m.
Pivotal Data Demonstrating Efficacy of Darusentan in Treating Resistant Hypertension Published in The Lancet
Printer Friendly Version 
September 11, 2009 - 4:31 p.m.
Gilead Sciences to Present at Three Upcoming Investor Conferences
Printer Friendly Version 
September 02, 2009 - 4:30 p.m.
Gilead Sciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on Wednesday, September 9
Printer Friendly Version 
August 19, 2009 - 8:30 a.m.
Gilead Sciences' Executive Vice President Establishes Rule 10b5-1 Stock Trading Plan
Printer Friendly Version 
August 14, 2009 - 6:01 p.m.
Gilead Sciences Receives Subpoena from U.S. Department of Health & Human Services Regarding Ranexa(R)
Printer Friendly Version 
August 03, 2009 - 4:19 p.m.
Gilead Announces Senior Management Promotion
Printer Friendly Version 
July 29, 2009 - 4:17 p.m.
Kevin E. Lofton Joins Gilead Sciences' Board of Directors
Printer Friendly Version 
July 21, 2009 - 4:07 p.m.
Gilead Sciences Announces Record Second Quarter 2009 Financial Results
Printer Friendly Version 
July 21, 2009 - 8:31 a.m.
Landmark Five-Year African Study Indicates That HIV Therapy May Be Given Safely in Resource-Limited Settings Without Routine Laboratory Monitoring
Printer Friendly Version 
July 16, 2009 - 4:31 p.m.
Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize New Fixed-Dose Combination of Truvada(R) and TMC278
Printer Friendly Version 
July 14, 2009 - 4:32 p.m.
Gilead Sciences to Release Second Quarter 2009 Financial Results on Tuesday, July 21, 2009
Printer Friendly Version 
June 26, 2009 - 8:30 a.m.
European CHMP Adopts Positive Opinion for Aztreonam Lysine
Printer Friendly Version 
June 18, 2009 - 4:30 p.m.
Gilead Sciences to Present at the Piper Jaffray 4th Annual Europe Conference on Wednesday, June 24
Printer Friendly Version 
June 02, 2009 - 4:30 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
May 28, 2009 - 4:30 p.m.
Gilead Sciences' Marketing Authorisation Application for Regadenoson Validated by European Medicines Agency
Printer Friendly Version 
May 22, 2009 - 4:31 p.m.
Gilead Sciences Announces Changes to Cardiovascular R&D Organization Leadership
Printer Friendly Version 
May 18, 2009 - 11:17 a.m.
New Data for Gilead Sciences' Ambrisentan Show Clinical Improvements in a Diverse Pulmonary Hypertension (PH) Population
Printer Friendly Version 
May 15, 2009 - 4:32 p.m.
Gilead Sciences to Present at the Deutsche Bank 34th Annual Healthcare Conference on Tuesday, May 19
Printer Friendly Version 
May 14, 2009 - 4:30 p.m.
Gilead Sciences Files Second Patent Infringement Lawsuit Against Teva Pharmaceuticals
Printer Friendly Version 
May 12, 2009 - 11:44 a.m.
Gilead Palo Alto, Inc. Announces Tender Offer for Convertible Notes
Printer Friendly Version 
May 08, 2009 - 8:30 a.m.
Gilead Sciences' Phase III Darusentan Data Show Significant Blood Pressure Reductions in Resistant Hypertension Patients
Printer Friendly Version 
April 21, 2009 - 4:07 p.m.
Gilead Sciences Announces Record First Quarter 2009 Financial Results
Printer Friendly Version 
April 17, 2009 - 4:17 p.m.
Gilead Sciences Completes Acquisition of CV Therapeutics
Printer Friendly Version 
April 17, 2009 - 8:30 a.m.
Gilead Initiates Phase II Clinical Trial of Integrase-Based, Single-Tablet, Once-Daily Regimen for the Treatment of HIV
Printer Friendly Version 
April 15, 2009 - 8:30 a.m.
Gilead Sciences Successfully Completes Tender Offer for Shares of CV Therapeutics With Over 88 Percent of Shares Tendered
Printer Friendly Version 
April 14, 2009 - 4:18 p.m.
Gilead Sciences to Release First Quarter 2009 Financial Results on Tuesday, April 21, 2009
Printer Friendly Version 
April 13, 2009 - 8:32 a.m.
Phase III Data for Gilead Sciences' Darusentan Accepted as Late-Breaker Presentation at ASH 2009
Printer Friendly Version 
April 06, 2009 - 5:02 p.m.
Gilead Sciences Announces Notification of ANDA Filing for Atripla(R)
Printer Friendly Version 
April 02, 2009 - 5:23 p.m.
Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints
Printer Friendly Version 
March 31, 2009 - 6:31 p.m.
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period
Printer Friendly Version 
March 24, 2009 - 4:17 p.m.
Gilead Initiates Phase II Clinical Trial of Cicletanine for the Treatment of Pulmonary Arterial Hypertension
Printer Friendly Version 
March 19, 2009 - 12:32 p.m.
European CHMP Adopts Negative Opinion on Aztreonam Lysine
Printer Friendly Version 
March 13, 2009 - 10:52 p.m.
Department of Justice Declines to Intervene in False Claims Act Lawsuits Against Gilead Sciences
Printer Friendly Version 
March 12, 2009 - 8:08 a.m.
Gilead Sciences Agrees to Acquire CV Therapeutics for $20.00 Per Share
Printer Friendly Version 
March 11, 2009 - 4:22 p.m.
Gilead Sciences to Present at the Cowen and Company 29th Annual Healthcare Conference on Monday, March 16
Printer Friendly Version 
March 06, 2009 - 4:17 p.m.
Gilead Sciences to Present at the Barclays Capital Global Healthcare Conference on Tuesday, March 10
Printer Friendly Version 
February 18, 2009 - 8:50 p.m.
Gilead Receives Response From U.S. FDA on Company's Request for Formal Dispute Resolution for Aztreonam for Inhalation Solution
Printer Friendly Version 
February 09, 2009 - 12:02 p.m.
Gilead Announces Data Demonstrating Pharmacokinetic Boosting Activity of GS 9350
Printer Friendly Version 
February 06, 2009 - 4:16 p.m.
Gilead Sciences to Present at the 11th Annual BIO CEO Investor Conference on Tuesday, February 10
Printer Friendly Version 
February 02, 2009 - 2:02 p.m.
Gilead Announces Senior Management Promotion
Printer Friendly Version 
January 29, 2009 - 4:16 p.m.
Gilead Completes Acquisition of Building and Associated Land from EFI
Printer Friendly Version 
January 27, 2009 - 6:02 p.m.
Gilead Outlines R&D Priorities for 2009
Printer Friendly Version 
January 27, 2009 - 4:07 p.m.
Gilead Sciences Announces Record Fourth Quarter and Full Year 2008 Financial Results
Printer Friendly Version 
January 16, 2009 - 4:17 p.m.
Gilead Sciences to Release Fourth Quarter and Year End 2008 Financial Results on Tuesday, January 27, 2009
Printer Friendly Version 
January 07, 2009 - 4:32 p.m.
Gilead Sciences to Present at the 27th Annual JPMorgan Healthcare Conference on Monday, January 12
Printer Friendly Version 
NASDAQ (US Dollar)
$75.57
 Stock is Up 1.23 (1.65%)
Data as of 12/15/17 4:15 p.m. ET
Minimum 20 minute delay
Refresh Quote